Recently, a TPT member asked us to run Syndax Pharmaceuticals (SNDX) through our IOMachine. IOMachine is a TPT initiative that produces quick and dirty opinion on biopharma stocks. So we ran it through the machine, and the following is the result.
The stock went down drastically following less than satisfactory data from the ENCORE 601 trial of entinostat in combination with Keytruda in an array of cancers like NSCLC and melanoma. However, entinostat has a number of trials ongoing in various indications, with the most advanced being the ER2112 301 trial in HR+,